Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1852 (LINC01852)
- Target
- LINC01852
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic RNA, Regulatory RNA
01
Overview
LINC01852 (Long intergenic non-protein coding RNA 1852) is a long non-coding RNA found to be downregulated in colorectal cancer. Functional studies demonstrate that LINC01852 suppresses tumorigenesis and chemoresistance by binding serine/arginine-rich splicing factor 5 (SRSF5) and promoting its degradation via TRIM72-mediated ubiquitination, which inhibits SRSF5-dependent alternative splicing of the pyruvate kinase M (PKM) gene, shifting metabolism from glycolysis to oxidative phosphorylation. These effects attenuate cancer cell growth and resistance to chemotherapy, positioning LINC01852 as a promising therapeutic and prognostic biomarker in CRC[2][3][5].
- Other names
- LINC01852ENST00000434223
02
Mechanism of action
When targeted (e.g., overexpressed experimentally), LINC01852 inhibits tumorigenesis and chemoresistance by suppressing SRSF5-mediated alternative splicing of PKM, therefore reducing PKM2-dependent glycolysis and promoting oxidative phosphorylation in CRC cells
03
Biological functions
Regulation of alternative splicing (specifically suppressing SRSF5-mediated alternative splicing of PKM)Inhibition of aerobic glycolysis (by decreasing PKM2 production)Modulation of ubiquitination and protein degradation (promotes TRIM72-mediated ubiquitination of SRSF5)Negative regulation of cell proliferationChemoresistance attenuation
04
Disease associations
Cancer (specifically colorectal cancer)Chemoresistance (in CRC)
05
Safety considerations
No clinical studies reported; unknown safety concerns for therapeutic manipulation in humans
06
Biomarkers
LINC01852 expression level (as a potential biomarker of tumor suppression and chemosensitivity in CRC)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1852 (LINC01852).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1852 (LINC01852).